Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis

References

• Vasala M, Immonen K, Kautiainen H, Hakala M. More evidence of declining incidence of amyloidosis associated with inflammatory rheumatic diseases. Scand J Rheumatol. 2010;39(6):461–5.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358(9275):24–9.
   PubMed Web of Science ®Google Scholar
• Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum. 2002;46(10):2571–3.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritis: a follow-up report of tolerability and efficacy. Arthritis Rheum. 2003;48(7):2019–24.
   PubMed Web of Science ®Google Scholar
• Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ. Treatment of renal amyloidosis with etanercept in tumor necrosis factor receptor-associated periodic syndrome. Rheumatology(Oxford). 2004;43(11):1405–8.
   PubMed Web of Science ®Google Scholar
• Kuroda H, Otaki Y, Sato H, Fujiwara T, Nakatsue T, Murakami S, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. Rheumatol Int. 2008; 28(11):1155–9.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S, et al. Effective anti-TNF-ectively treated with Infliximab. infliximsustaind decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol. 2009;36(11):2409–15.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol. 2010;29(12);1395–401.
   PubMed Web of Science ®Google Scholar
• Fernandes-Nebro A, Olive A, Castro MC, Varela AH, Riera E, Irigoyen MV, et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010;123(5):456–61.
   Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 receptor antibody(SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–7.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761–9.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll G, Balint G, et al. Double-blind randomized controlled clinical trials of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–29.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619–26.
   PubMedGoogle Scholar
• Nishida S, Hagihara K, Shima Y, Kawai M, Kuwahara Y, Arimitsu J, et al. Rapid improvement of AA amyloidosis with humanized anti-interleukin 6 receptor treatment. Ann Rheum Dis. 2009;68(7):1235–6.
   PubMed Web of Science ®Google Scholar
• Sato H, Sakai T, Sugaya T, Otaki Y, Aoki K, Ishii K, et al. Tocilizumab dramatically ameliorated life-threating diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009;28(9):1113–6.
   PubMed Web of Science ®Google Scholar
• Inoue D, Arima H, Kawanami C, Takiuchi Y, Nagano S, Kimura T, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010;29(10):1195–7.
   PubMed Web of Science ®Google Scholar
• Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54(9):2997–3000.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089–100.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells. 2005;10(11):1051–63.
   PubMed Web of Science ®Google Scholar
• Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin Hematol. 2000;7(1):64–9.
   PubMed Web of Science ®Google Scholar
• Niewold TA, Gruys E, Arakawa T, Shirahama T, Kisilevsky R. Recombinant human tumor necrosis factor-alpha(rhTNF-alpha) and rhTNF-alpha analogue enhance amyloid deposition in the Syrian hamster. Scand J Immunol. 1993;37(1):29–32.
   PubMed Web of Science ®Google Scholar
• Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA Amyloidosis in Rheumatic Diseases: A Critical Overview. Arthritis Rheum. 2009;61(10):1435–40.
   PubMed Web of Science ®Google Scholar
• Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A(SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314: 363–9.
   PubMed Web of Science ®Google Scholar
• Yoshizaki K. Pathogenic analysis of chronic inflammatory disease based on the clinical results by IL-6 blocking therapy(in Japanese). Nihon Rinsho Meneki Gakkai Kaishi 2008;3:104–12.
   Google Scholar